

By Speed Post

मिसिल संख्या 10(Sec.26.2.0.3)/2014/(एनपीपीए)-डिवी. II

भारत सरकार

रसायन एवं उर्वरक मंत्रालय

औषध विभाग

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

तीसरी/पाचवी मंजिल,

वाई०एम०सी०ए० सांस्कृतिक केन्द्र भवन,

1, जय सिंह मार्ग, नई दिल्ली-110001

दिनांक-12-07-2016

To,

The Managing Director/C.E.O.

M/s. Axa Parenterals Ltd.

“Axa House”, Vill Kishanpur Jamalpur,

Puhana Chowk (Bhagwapur), Roorkee-247667

Haridwar, U.K.

Sub.: Ceiling prices for scheduled formulation packs of I.V. Fluids vide S.O. No., 2209(E) and 2210(E) dated 24.6.2016 – Clarification.

Sir,

I am directed to refer to your office letter no. nil dated 1.7.2016 (received on 5.7.2016) for above mentioned subject. In this regard, you are requested to refer para 13(2) of DPCO, 2013 which states that all the existing manufacturers of Scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price lower than the ceiling price (plus local taxes as applicable) so fixed and notified by the government shall maintain their existing maximum retail price (MRP).

2. Since, it was a review case & the base data considered was of September, 2013, thus, existing manufacturer may take into consideration the applicable WPIs for the years 2013, 2014 & 2015 on their respective the then prevalent MRPs & may change MRPs accordingly.

3. You are, therefore, requested to submit the compliance report in Form-V of DPCO, 2013.

Yours Faithfully



(ए. के. खुराना)

निदेशक (प्राइसिंग)